Back to Agenda
Session 3 Track 1: Clinical Development of Oligonucleotide Therapeutics for Viral and Kidney Diseases
Session Chair(s)
Laura Sepp-Lorenzino, PhD
Chief Scientific Officer, Intellia Therapeutics, Inc., United States
Zheng Li Li, PhD
Pharmacologist, FDA, United States
This session will provide updates on siRNAs in clinical development for chronic hepatitis and cancer. Liver-targeted silencers of Hepatitis B Virus are being developed in combination with viral life cycle inhibitors and immune enhancing therapies, with the goal of breaking tolerance and establishing a functional cure in chronic hepatitis B patients. Phase ½ mono and combination therapy data for two HBV silencers will be presented. The last talk will highlight the clinical experience with an extra-hepatic siRNA candidate being developed for renal cell carcinoma, targeting HIF2.
Learning Objective : At the conclusion of this session, participants should be able to:
- Compare and contrast various oligonucleotide modalities and their applications
- Recognize clinical development considerations and trial designs for mono and combination therapies
- Discuss data from most advanced oligonucleotide drug/candidates for liver and kidney disease targets
Speaker(s)
Daniel Cloutier, PharmD
Senior Director, Clinical Research, Clinical Lead, HBV Program, Vir Biotechnology, Inc., United States
Clinical Development of VIR-2218, a GalNAc-siRNA Targeting Hepatitis B, in Combination with Immune Enhancing Therapies
Michael Biermer, MD
Senior Medical Director, Clinical Development, Janssen Pharmaceuticals, Belgium
Short Interfering RNA JNJ-3989 Combination Therapy
James Hamilton, MD, MBA
Chief of Discovery and Transitional Medicine, Arrowhead Pharmaceuticals, United States
ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma Ph1b
Have an account?